NDA 220963 · Rare Thyroid
Emcitate
Tiratricol · Oral
NovelPriority reviewOrphanCDER novel approval, Sep 28, 2026: To treat peripheral thyrotoxicosis in patients with MCT8 deficiency
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Sep 28, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
3
1 Phase 3, 0 recruiting
FAERS reports
15
13 serious, 1 with death reported
AI brief across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including EMCITATE, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss [see Warnings and Precautions ( 5.2 )]. WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS See full prescribing information for complete boxed warning. Thyroid hormones, including EMCITATE, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. ( 5.2 )
What it is approved for
From the label in effect Oct 1, 2026.
EMCITATE is indicated for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan-Herndon-Dudley syndrome). EMCITATE is a thyroid hormone receptor agonist indicated for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan-Herndon-Dudley syndrome). Limitation of Use EMCITATE is not recommended for the treatment of primary hypothyroidism. Limitation of Use EMCITATE is not recommended for the treatment of primary hypothyroidism.
Mechanism: Tiratricol is a thyroid hormone receptor (THR) agonist which, unlike triiodothyronine (T3) and thyroxine (T4), can enter cells independent of the transmembrane transporter protein MCT8. In patients with MCT8 deficiency, X-linked loss-of-function mutations in the SLC16A2 gene encoding MCT8 impair T3 entry into target tissues. This results in insufficient T3 activity in the brain concurrent with persistent peripheral thyrotoxicosis from accumulation of circulating T3. Intracellular tiratricol activity at THR-β, independent of MCT8-mediated membrane transport, can modulate...
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 28, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabel
1 products under this application
- EMCITATE · TIRATRICOL 350MCG · TABLET, FOR SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tiratricol" as an intervention, any sponsor and status, largest first.
Erasmus Medical CenterAcademic, hospital or other
NCT02060474 · 46 participants · Start Oct 2014 · Primary completion Jun 26, 2018
Drug: Triac · For: Allan-Herndon-Dudley Syndrome
Sites: Rotterdam, Netherlands
- Triac Trial II in MCT8 Deficiency PatientsActive, not recruiting
Rare Thyroid Therapeutics International ABIndustry
NCT02396459 · 22 participants · Start Dec 7, 2020 · Primary completion Jul 18, 2027
Drug: Tiratricol · For: Allan-Herndon-Dudley Syndrome
Sites: Portland, Oregon; Philadelphia, Pennsylvania; Prague, Czechia · 5 sites in all
- Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)Pivotal-lookingCompleted
Rare Thyroid Therapeutics International ABIndustry
NCT05579327 · 20 participants · Start Jul 21, 2023 · Primary completion Jul 22, 2025
Drug: Tiratricol; Placebo · For: Monocarboxylate Transporter 8 Deficiency; Allan-Herndon-Dudley Syndrome
Sites: Kissimmee, Florida; Atlanta, Georgia; St Louis, Missouri · 8 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- apraxia4
- hypokalaemia4
- mydriasis4
- syncope4
- thyroid disorder4
- acute coronary syndrome3
- off label use3
- alanine aminotransferase increased2
- cardiac arrest2
- head injury2
- intentional product misuse2
- toxicity to various agents2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2007 | 1 |
| 2010 | 1 |
| 2013 | 4 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Augmented hepatic and skeletal thyromimetic effects of tiratricol in comparison with levothyroxine.
Sherman SI, Ringel MD, Smith MJ, et al. · J Clin Endocrinol Metab 1997 · Clinical Trial, Comparative Study
- Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial.
Groeneweg S, Peeters RP, Moran C, et al. · Lancet Diabetes Endocrinol 2019 · Clinical Trial, Phase II, Multicenter Study
- Organ-specific effects of tiratricol: a thyroid hormone analog with hepatic, not pituitary, superagonist effects.
Sherman SI, Ladenson PW · J Clin Endocrinol Metab 1992 · Clinical Trial, Randomized Controlled Trial
Sponsor: Rare Thyroid
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.